Vildagliptin-d7

CAT: 0804-HY-14291S1Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-14291S1Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Vildagliptin-d7 is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].
CAS Number
[1133208-42-0]
Product Name Alternative
LAF237-d7; NVP-LAF 237-d7
UNSPSC
12352005
Hazard Statement
H302
Target
Apoptosis; Dipeptidyl Peptidase; Ferroptosis; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Metabolic Enzyme/Protease; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Solubility
10 mM in DMSO
Smiles
[2H]C1([2H])C([2H])([2H])C([2H])([2H])[C@@]([2H])(C#N)N1C(CNC2(C3)CC4(O)CC3CC(C4)C2)=O
Molecular Formula
C17H18D7N3O2
Molecular Weight
310.44
Precautions
P264-P270-P330-P501
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Villhauer EB, et al. 1-[[ (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano- (S) -pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46 (13) :2774-89.|[3]Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64 (2) :226-35.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
DPP-4

Popular Products